MedPath

Effects of DHEA/Exercise on Bone, Muscle and Balance

Phase 4
Completed
Conditions
Osteoporosis
Frailty
Interventions
Dietary Supplement: DHEA
Behavioral: Yoga
Behavioral: Aerobics
Dietary Supplement: Placebo
Registration Number
NCT00664053
Lead Sponsor
National Aeronautics and Space Administration (NASA)
Brief Summary

The purpose of this study is to examine whether muscle strength and balance will improve in women with frailty selected for dehydroepiandrosterone sulfate (DHEAS) levels below 550 ng/dl treated with DHEAS supplementation and Hatha yoga. Investigators believe the effects of both treatments will improve outcomes more than either treatment alone and may be additive; in addition, lean body mass, skeletal muscle mass, markers of bone turnover and physical performance will improve following treatment with DHEA and/or yoga.

Detailed Description

Dehydroepiandrosterone (DHEAS) and yoga may mitigate or reverse the effects of aging and frailty on bone, muscle and balance loss. The mechanism of the effects may be direct - working through androgen or estrogen receptors in bone, muscle or brain. Or the effects may be indirect, countering effects of the stress response.

The specific aims of this study are:

1. To determine the effects of dehydroepiandrosterone sulfate (DHEAS) supplementation and/or Hatha yoga on muscle strength, balance, body composition and physical performance measures over 6 months in women with osteopenia and some degree of frailty

2. To determine the effect of dehydroepiandrosterone sulfate (DHEAS) supplementation and/or Hatha yoga on function (physical and cognitive), bone metabolism, and cardiovascular risk factors.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
99
Inclusion Criteria
  • Women over age 65 years
  • Bone mineral density t-score less than -1
  • At least one of the five components of the frailty phenotype (low hand grip strength, low walking speed, low physical activity, weight loss or sense of exhaustion)
  • DHEAS levels less than 550 ng/dl
  • Able to come or be brought to the University of Connecticut Health Center (UCHC) for outpatient visits
  • Mammogram within the preceding 12 months
Exclusion Criteria
  • Disease or medication known to affect bone or muscle metabolism (i.e., Paget's disease, osteomalacia or 25OHD level less than 10 ng/dl, hyperparathyroidism: current use of corticosteroids, calcitonin, heparin, phenytoin, phenobarbital, methotrexate, bisphosphonates, calcitonin, selective estrogen receptor modulator or PTH)
  • Use of androgen or estrogen in the preceding year
  • Use of psychiatric medications including antipsychotic medications and SSRI
  • Metastatic or advanced cancer (other than skin cancer)
  • History of breast cancer
  • Active cardiac ischemia by history of angina or myocardial infarction in the preceding 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
1YogaDHEA and Yoga
1DHEADHEA and Yoga
2DHEADHEA and exercise
2AerobicsDHEA and exercise
3YogaPlacebo and Yoga
3PlaceboPlacebo and Yoga
4PlaceboPlacebo and exercise
4AerobicsPlacebo and exercise
Primary Outcome Measures
NameTimeMethod
Muscle strength, bone turnover markersbaseline, 3 month and 6 months
Secondary Outcome Measures
NameTimeMethod
Changes in activities of daily living, cognitive and emotional functionbaseline and 6 months
Laboratory tests to measure factors that may reflect or influence changes in bone metabolismbaseline and 6 months

Trial Locations

Locations (1)

University of Connecticut Health Center

🇺🇸

Farmington, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath